Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms

Johannes Hofland, Gregory Kaltsas, Wouter W de Herder, Johannes Hofland, Gregory Kaltsas, Wouter W de Herder

Abstract

Neuroendocrine neoplasms constitute a diverse group of tumors that derive from the sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary and gastrointestinal tracts. The majority of these neoplasms have a well-differentiated grade and are termed neuroendocrine tumors (NETs). This subgroup is characterized by limited proliferation and patients affected by these tumors carry a good to moderate prognosis. A substantial subset of patients presenting with a NET suffer from the consequences of endocrine syndromes as a result of the excessive secretion of amines or peptide hormones, which can impair their quality of life and prognosis. Over the past 15 years, critical developments in tumor grading, diagnostic biomarkers, radionuclide imaging, randomized controlled drug trials, evidence-based guidelines, and superior prognostic outcomes have substantially altered the field of NET care. Here, we review the relevant advances to clinical practice that have significantly upgraded our approach to NET patients, both in diagnostic and in therapeutic options.

© Endocrine Society 2020.

Figures

Graphical Abstract
Graphical Abstract
Figure 1.
Figure 1.
Neuroendocrine neoplasms (NEN) locations and incidence rates. The most common primary NEN sites of the pulmonary and gastroenteropancreatic systems are depicted. Incidence rates were collected from Fraenkel et al. (9). and Dasari et al. (8). and are shown in red as the incident number of cases per 100 000 per year.
Figure 2.
Figure 2.
Clinical signs of hormonal excess in neuroendocrine neoplasms (NENs). (A) Facial flushing in the context of carcinoid syndrome in a patient with a metastasized midgut neuroendocrine tumor. (B) Necrolytic migratory erythema at the sacral region and (C) glossitis in a patient with a metastasized glucagonoma.
Figure 3.
Figure 3.
Histopathology of neuroendocrine neoplasms (NENs). Hematoxylin and eosin (H&E, A) and Ki67 (B) staining of a grade 1 NET showing nests of neuroendocrine cells with oval nuclei, “salt and paper” chromatin and moderate eosinophilic cytoplasm. The nests are separated by a fibrous stroma. Nuclear staining of Ki67 is only visible in a few neoplastic cells (Ki67

Figure 4.

Imaging procedures used in neuroendocrine…

Figure 4.

Imaging procedures used in neuroendocrine neoplasm (NEN) diagnostics. (A) Axial T2-weighted magnetic resonance…

Figure 4.
Imaging procedures used in neuroendocrine neoplasm (NEN) diagnostics. (A) Axial T2-weighted magnetic resonance imaging (MRI) showing metastatic deposits in both hepatic lobes from a pancreatic Grade 2 NET. (B) Axial T1 diffusion MRI image of the same patient showing further lesions not detected with the previous MRI sequence. (C) Computed tomography (CT) of the abdomen demonstrating a desmoplastic reaction (white arrow) in the mesentery of a patient with a Grade 1 small bowel NET. (D) Fibrotic strands radiating from a central mesenteric metastatic mass in a patient with multiple small bowel NETs. There is thickening of the bowel wall and fluid retention due to venous ischemia in this patient, causing postprandial abdominal pain. (E) MRI T2-weighted image with fat saturation demonstrating an oval shaped high signal bone lesion from a Grade 2 small bowel NET at the level of Th11 (white arrow). (F) Polypoid lesion arising from the body of the stomach detected by endoscopic ultrasonography infiltrating the mucosa and submucosa. (G) Positive right hepatic lobe 18F-FDG PET uptake (white arrow) in a patient with a small bowel Grade 2 NET. In the same patient positive 68Gallium-DOTATOC positron emission tomography (PET) in the same area of 18F-FDG PET uptake (thick white arrow) and additional uptake in different areas of the left hepatic lobe (thin white arrow). (H) Positive uptake in multiple hepatic areas in a patient with a Grade 2 pancreatic NET following a 68Gallium-DOTATOC PET. Negative 18F-FDG PET in tumor lesions within the same patient.

Figure 5.

Diagnostic algorithm. Histology should be…

Figure 5.

Diagnostic algorithm. Histology should be obtained from tumors suspected of NEN to confirm…

Figure 5.
Diagnostic algorithm. Histology should be obtained from tumors suspected of NEN to confirm the diagnosis of a neuroendocrine origin. Morphological examination will subsequently divide neoplasms into well-differentiated tumors or poorly differentiated carcinomas. Uncertain cases can be categorized through the use of genetic analysis or p53 staining. Within the NETs mitotic and Ki-67 indices will classify the tumor into grade 1 to 3. Further prognostic and therapeutic information can be obtained by performing 68Ga-labelled somatostatin receptor imaging and for higher grade or clinically aggressive tumors an 18F-FDG PET. FDG, fluorodeoxyglucose NEN, neuroendocrine neoplasm; WD, well-differentiated; PD, poorly differentiated; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; SUV, standardized uptake value; PET, positron emission tomography; Pan, pancreas; GI, gastrointestinal.

Figure 6.

Therapeutic targets for neuroendocrine neoplasms…

Figure 6.

Therapeutic targets for neuroendocrine neoplasms (NENs). Overview of the different therapeutic modalities for…

Figure 6.
Therapeutic targets for neuroendocrine neoplasms (NENs). Overview of the different therapeutic modalities for proliferative control in NENs and their respective targets within the NEN cell.
All figures (7)
Figure 4.
Figure 4.
Imaging procedures used in neuroendocrine neoplasm (NEN) diagnostics. (A) Axial T2-weighted magnetic resonance imaging (MRI) showing metastatic deposits in both hepatic lobes from a pancreatic Grade 2 NET. (B) Axial T1 diffusion MRI image of the same patient showing further lesions not detected with the previous MRI sequence. (C) Computed tomography (CT) of the abdomen demonstrating a desmoplastic reaction (white arrow) in the mesentery of a patient with a Grade 1 small bowel NET. (D) Fibrotic strands radiating from a central mesenteric metastatic mass in a patient with multiple small bowel NETs. There is thickening of the bowel wall and fluid retention due to venous ischemia in this patient, causing postprandial abdominal pain. (E) MRI T2-weighted image with fat saturation demonstrating an oval shaped high signal bone lesion from a Grade 2 small bowel NET at the level of Th11 (white arrow). (F) Polypoid lesion arising from the body of the stomach detected by endoscopic ultrasonography infiltrating the mucosa and submucosa. (G) Positive right hepatic lobe 18F-FDG PET uptake (white arrow) in a patient with a small bowel Grade 2 NET. In the same patient positive 68Gallium-DOTATOC positron emission tomography (PET) in the same area of 18F-FDG PET uptake (thick white arrow) and additional uptake in different areas of the left hepatic lobe (thin white arrow). (H) Positive uptake in multiple hepatic areas in a patient with a Grade 2 pancreatic NET following a 68Gallium-DOTATOC PET. Negative 18F-FDG PET in tumor lesions within the same patient.
Figure 5.
Figure 5.
Diagnostic algorithm. Histology should be obtained from tumors suspected of NEN to confirm the diagnosis of a neuroendocrine origin. Morphological examination will subsequently divide neoplasms into well-differentiated tumors or poorly differentiated carcinomas. Uncertain cases can be categorized through the use of genetic analysis or p53 staining. Within the NETs mitotic and Ki-67 indices will classify the tumor into grade 1 to 3. Further prognostic and therapeutic information can be obtained by performing 68Ga-labelled somatostatin receptor imaging and for higher grade or clinically aggressive tumors an 18F-FDG PET. FDG, fluorodeoxyglucose NEN, neuroendocrine neoplasm; WD, well-differentiated; PD, poorly differentiated; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; SUV, standardized uptake value; PET, positron emission tomography; Pan, pancreas; GI, gastrointestinal.
Figure 6.
Figure 6.
Therapeutic targets for neuroendocrine neoplasms (NENs). Overview of the different therapeutic modalities for proliferative control in NENs and their respective targets within the NEN cell.

References

    1. Perren A, Couvelard A, Scoazec JY, et al. ; Antibes Consensus Conference participants . ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology. 2017;105(3):196–200.
    1. Inzani F, Petrone G, Rindi G. The New World Health Organization classification for pancreatic neuroendocrine neoplasia. Endocrinol Metab Clin North Am. 2018;47(3):463–470.
    1. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25(3):458–511.
    1. Asa SL, Casar-Borota O, Chanson P, et al. ; attendees of 14th Meeting of the International Pituitary Pathology Club, Annecy, France, November 2016. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017;24(4):C5–C8.
    1. Schadendorf D, Lebbé C, Zur Hausen A, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017;71:53–69.
    1. Cardoso FA, Monteiro EMR, Lopes LB, Avila MNDC, Scarioli BO. Adenomatous tumors of the middle ear: a literature review. Int Arch Otorhinolaryngol. 2017;21(3):308–312.
    1. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–1786.
    1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.
    1. Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD; Knowledge NETwork . Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153–R163.
    1. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–918.
    1. Sadowski SM, Neychev V, Millo C, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34(6):588–596.
    1. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707–712.
    1. Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol. 2013;168(2):185–193.
    1. Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004;136(6):1267–1274.
    1. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20(2):168–172.
    1. Pape UF, Niederle B, Costa F, et al. ; Vienna Consensus Conference participants . ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology. 2016;103(2):144–152.
    1. Ramage JK, De Herder WW, Delle Fave G, et al. ; Vienna Consensus Conference participants . ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):139–143.
    1. Lee MR, Harris C, Baeg KJ, Aronson A, Wisnivesky JP, Kim MK. Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States. Clin Gastroenterol Hepatol. 2019;17(11):2212–2217.e1.
    1. Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017;58(2):368–379.
    1. Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45(2):234–243.
    1. Mafficini A, Scarpa A. Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms. Endocr Rev. 2019;40(2):506–536.
    1. Thakker RV, Newey PJ, Walls GV, et al. ; Endocrine Society . Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011.
    1. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059–2067.
    1. Relles D, Baek J, Witkiewicz A, Yeo CJ. Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases. J Gastrointest Surg. 2010;14(6):1052–1061.
    1. Därr R, Nambuba J, Del Rivero J, et al. Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. Endocr Relat Cancer. 2016;23(12):899–908.
    1. Yu R. Mahvash disease: 10 years after discovery. Pancreas. 2018;47(5):511–515.
    1. Iacovazzo D, Flanagan SE, Walker E, et al. MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. Proc Natl Acad Sci U S A. 2018;115(5):1027–1032.
    1. Dimitriadis GK, Angelousi A, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Paraneoplastic endocrine syndromes. Endocr Relat Cancer. 2017;24(6):R173–R190.
    1. Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–534.
    1. de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21(1):33–41.
    1. Grahame-Smith DG. Progress report: the carcinoid syndrome. Gut. 1970;11(2):189–192.
    1. Hofland J, Herrera Martinez AD, Zandee WT, de Herder WW. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer. 2019;26(3):R145–R156.
    1. Zandee WT, Kamp K, van Adrichem RC, Feelders RA, de Herder WW. Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. Endocr Relat Cancer. 2017;24(7):R261–R274.
    1. de Herder WW, Niederle B, Scoazec JY, et al. ; Frascati Consensus Conference; European Neuroendocrine Tumor Society . Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84(3):183–188.
    1. Cryer PE, Axelrod L, Grossman AB, et al. ; Endocrine Society . Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709–728.
    1. Rehfeld JF, Bardram L, Hilsted L, Poitras P, Goetze JP. Pitfalls in diagnostic gastrin measurements. Clin Chem. 2012;58(5):831–836.
    1. Jensen RT, Niederle B, Mitry E, et al. ; Frascati Consensus Conference; European Neuroendocrine Tumor Society . Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006;84(3):173–182.
    1. Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol. 2013;29(6):650–661.
    1. de Herder WW, Rehfeld JF, Kidd M, Modlin IM. A short history of neuroendocrine tumours and their peptide hormones. Best Pract Res Clin Endocrinol Metab. 2016;30(1):3–17.
    1. Peng SY, Li JT, Liu YB, et al. Diagnosis and treatment of VIPoma in China: (case report and 31 cases review) diagnosis and treatment of VIPoma. Pancreas. 2004;28(1):93–97.
    1. Kamp K, Feelders RA, van Adrichem RC, et al. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up. J Clin Endocrinol Metab. 2014;99(9):3060–3069.
    1. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore). 1996;75(2):53–63.
    1. Larsson LI, Hirsch MA, Holst JJ, et al. Pancreatic somatostatinoma. Clinical features and physiological implications. Lancet. 1977;1(8013):666–668.
    1. Crona J, Norlén O, Antonodimitrakis P, Welin S, Stålberg P, Eriksson B. Multiple and secondary hormone secretion in patients with metastatic pancreatic neuroendocrine tumours. J Clin Endocrinol Metab. 2016;101(2):445–452.
    1. de Mestier L, Hentic O, Cros J, et al. Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study. Ann Intern Med. 2015;162(10):682–689.
    1. Kamp K, Alwani RA, Korpershoek E, Franssen GJ, de Herder WW, Feelders RA. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors. Eur J Endocrinol. 2016;174(3):271–280.
    1. van Hoek M, Hofland LJ, de Rijke YB, et al. Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. J Clin Endocrinol Metab. 2009;94(2):428–433.
    1. Rehfeld JF, Federspiel B, Bardram L. A neuroendocrine tumor syndrome from cholecystokinin secretion. N Engl J Med. 2013;368(12):1165–1166.
    1. Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461–466.
    1. Blažević A, Hofland J, Hofland LJ, Feelders RA, de Herder WW. Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. Endocr Relat Cancer. 2018;25(3):R115–R130.
    1. Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch. 2018;472(3):341–349.
    1. Rindi G, Klöppel G, Alhman H, et al. ; all other Frascati Consensus Conference participants; European Neuroendocrine Tumor Society (ENETS) . TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395–401.
    1. Klöppel G, Couvelard A, Perren A, et al. ; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society . ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90(2):162–166.
    1. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72.
    1. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757–762.
    1. Klöppel G, Rindi G, Perren A, Komminoth P, Klimstra DS. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch. 2010;456(6):595–597.
    1. Yang MX, Coates RF, Ambaye A, et al. NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors. Biomark Res. 2018;6:15.
    1. Rindi G, Klersy C, Albarello L, et al. Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms: data from a large international cohort study. Neuroendocrinology. 2018;107(4):375–386.
    1. Sadanandam A, Wullschleger S, Lyssiotis CA, et al. A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics. Cancer Discov. 2015;5(12):1296–1313.
    1. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–160.
    1. Tang LH, Untch BR, Reidy DL, et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res. 2016;22(4):1011–1017.
    1. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–1203.
    1. Scarpa A, Chang DK, Nones K, et al. ; Australian Pancreatic Cancer Genome Initiative . Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543(7643):65–71.
    1. Stålberg P, Westin G, Thirlwell C. Genetics and epigenetics in small intestinal neuroendocrine tumours. J Intern Med. 2016;280(6):584–594.
    1. Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018;14(11):656–669.
    1. Oberg K, Krenning E, Sundin A, et al. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect. 2016;5(5):174–187.
    1. Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16(9):e435–e446.
    1. Oberg K, Couvelard A, Delle Fave G, et al. ; Antibes Consensus Conference participants . ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology. 2017;105(3):201–211.
    1. Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol. 2015;110(8):1223–1232.
    1. Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol. 2012;26(6):791–802.
    1. Marotta V, Zatelli MC, Sciammarella C, et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer. 2018;25(1):R11–R29.
    1. Rossi RE, Ciafardini C, Sciola V, Conte D, Massironi S. Chromogranin A in the follow-up of gastroenteropancreatic neuroendocrine neoplasms: is it really game over? A systematic review and meta-analysis. Pancreas. 2018;47(10):1249–1255.
    1. Ito T, Jensen RT. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):15–24.
    1. Stabile BE, Howard TJ, Passaro E Jr, O’Connor DT. Source of plasma chromogranin A elevation in gastrinoma patients. Arch Surg. 1990;125(4):451–453.
    1. Turner GB, Johnston BT, McCance DR, McGinty A, Watson RG, Patterson CC, Ardill JE. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut. 2006;55(11):1586–1591.
    1. Zandee WT, Kamp K, van Adrichem RC, Feelders RA, de Herder WW. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. Eur J Endocrinol. 2016;175(5):361–366.
    1. Davar J, Connolly HM, Caplin ME, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol. 2017;69(10):1288–1304.
    1. Laskaratos FM, Walker M, Wilkins D, et al. Evaluation of clinical prognostic factors and further delineation of the effect of mesenteric fibrosis on survival in advanced midgut neuroendocrine tumours. Neuroendocrinology. 2018;107(3):292–304.
    1. Adaway JE, Dobson R, Walsh J, et al. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem. 2016;53(Pt 5):554–560.
    1. Ito T, Hijioka S, Masui T, et al. Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. J Gastroenterol. 2017;52(1):9–18.
    1. Modlin IM, Oberg K, Taylor A, Drozdov I, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: current status and perspectives. Neuroendocrinology. 2014;100(4):265–277.
    1. Khan MS, Tsigani T, Rashid M, et al. Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res. 2011;17(2):337–345.
    1. Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol. 2013;31(3):365–372.
    1. Khan MS, Kirkwood AA, Tsigani T, et al. Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms. Clin Cancer Res. 2016;22(1):79–85.
    1. Boons G, Vandamme T, Peeters M, et al. Cell-free DNA from metastatic pancreatic neuroendocrine tumor patients contains tumor-specific mutations and copy number variations. Front Oncol. 2018;8:467.
    1. Malczewska A, Kidd M, Matar S, Kos-Kudla B, Modlin IM. A comprehensive assessment of the role of miRNAs as biomarkers in gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology. 2018;107(1):73–90.
    1. Rizzo FM, Meyer T. Liquid biopsies for neuroendocrine tumors: circulating tumor cells, DNA, and MicroRNAs. Endocrinol Metab Clin North Am. 2018;47(3):471–483.
    1. Kidd M, Drozdov I, Modlin I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. 2015;22(4):561–575.
    1. Bodei L, Kidd M, Modlin IM, et al. Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. Eur J Nucl Med Mol Imaging. 2015;42(9):1341–1352.
    1. van Treijen MJC, Korse CM, van Leeuwaarde RS, et al. Blood transcript profiling for the detection of neuroendocrine tumors: results of a large independent validation study. Front Endocrinol (Lausanne). 2018;9:740.
    1. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333(6041):425.
    1. Marinoni I, Kurrer AS, Vassella E, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146(2):453–460.e5.
    1. Cunningham JL, Díaz de Ståhl T, Sjöblom T, Westin G, Dumanski JP, Janson ET. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes Cancer. 2011;50(2):82–94.
    1. Choi IS, Estecio MR, Nagano Y, et al. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol. 2007;20(7):802–810.
    1. Edfeldt K, Ahmad T, Åkerström G, et al. TCEB3C a putative tumor suppressor gene of small intestinal neuroendocrine tumors. Endocr Relat Cancer. 2014;21(2):275–284.
    1. Karpathakis A, Dibra H, Pipinikas C, et al. Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor. Clin Cancer Res. 2016;22(1):250–258.
    1. Sundin A, Arnold R, Baudin E, et al. ; Antibes Consensus Conference participants . ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology. 2017;105(3):212–244.
    1. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–518.
    1. Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50(8):1214–1221.
    1. Pilleul F, Penigaud M, Milot L, Saurin JC, Chayvialle JA, Valette PJ. Possible small-bowel neoplasms: contrast-enhanced and water-enhanced multidetector CT enteroclysis. Radiology. 2006;241(3):796–801.
    1. Johanssen S, Boivin M, Lochs H, Voderholzer W. The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis. Gastrointest Endosc. 2006;63(4):660–665.
    1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
    1. Caramella C, Dromain C, De Baere T, Boulet B, Schlumberger M, Ducreux M, Baudin E. Endocrine pancreatic tumours: which are the most useful MRI sequences? Eur Radiol. 2010;20(11):2618–2627.
    1. Brenner R, Metens T, Bali M, Demetter P, Matos C. Pancreatic neuroendocrine tumor: added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection. Eur J Radiol. 2012;81(5):e746–e749.
    1. d’Assignies G, Fina P, Bruno O, et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology. 2013;268(2):390–399.
    1. Couvelard A, O’Toole D, Turley H, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2005;92(1):94–101.
    1. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1-2):2–15.
    1. Puli SR, Kalva N, Bechtold ML, et al. Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a systematic review and meta analysis. World J Gastroenterol. 2013;19(23):3678–3684.
    1. Weynand B, Borbath I, Bernard V, et al. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index. Cytopathology. 2014;25(6):389–395.
    1. Boutsen L, Jouret-Mourin A, Borbath I, van Maanen A, Weynand B. Accuracy of pancreatic neuroendocrine tumour grading by endoscopic ultrasound-guided fine needle aspiration: analysis of a large cohort and perspectives for improvement. Neuroendocrinology. 2018;106(2):158–166.
    1. Hwang HS, Kim Y, An S, et al. Grading by the Ki-67 labeling index of endoscopic ultrasound-guided fine needle aspiration biopsy specimens of pancreatic neuroendocrine tumors can be underestimated. Pancreas. 2018;47(10):1296–1303.
    1. Panagiotidis E, Alshammari A, Michopoulou S, et al. Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med. 2017;58(1):91–96.
    1. Van Binnebeek S, Vanbilloen B, Baete K, et al. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol. 2016;26(3):900–909.
    1. Johnbeck CB, Knigge U, Kjær A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10(14):2259–2277.
    1. Velikyan I, Sundin A, Sörensen J, et al. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014;55(2):204–210.
    1. Barrio M, Czernin J, Fanti S, et al. The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med. 2017;58(5):756–761.
    1. Cescato R, Waser B, Fani M, Reubi JC. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52(12):1886–1890.
    1. van Adrichem RC, Kamp K, van Deurzen CH, et al. Is there an additional value of using somatostatin receptor subtype 2a immunohistochemistry compared to somatostatin receptor scintigraphy uptake in predicting gastroenteropancreatic neuroendocrine tumor response? Neuroendocrinology. 2016;103(5):560–566.
    1. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978–985.
    1. Sansovini M, Severi S, Ianniello A, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE. Eur J Nucl Med Mol Imaging. 2017;44(3):490–499.
    1. Bahri H, Laurence L, Edeline J, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014;55(11):1786–1790.
    1. Has Simsek D, Kuyumcu S, Turkmen C, et al. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med. 2014;55(11):1811–1817.
    1. Luo Y, Pan Q, Yao S, et al. Glucagon-like peptide-1 receptor PET/CT with 68Ga-NOTA-Exendin-4 for detecting localized insulinoma: a prospective cohort study. J Nucl Med. 2016;57(5):715–720.
    1. Antwi K, Fani M, Heye T, et al. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. Eur J Nucl Med Mol Imaging. 2018;45(13):2318–2327.
    1. Balogova S, Talbot JN, Nataf V, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013;40(6):943–966.
    1. Putzer D, Gabriel M, Kendler D, et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging. 2010;54(1):68–75.
    1. Werner RA, Weich A, Higuchi T, et al. Imaging of chemokine receptor 4 expression in neuroendocrine tumors - a triple tracer comparative approach. Theranostics. 2017;7(6):1489–1498.
    1. Neyman K, Sundset A, Naalsund A, et al. Endoscopic treatment of bronchial carcinoids in comparison to surgical resection: a retrospective study. J Bronchol Interv Pulmonol. 2012;19(1):29–34.
    1. Luckraz H, Amer K, Thomas L, Gibbs A, Butchart EG. Long-term outcome of bronchoscopically resected endobronchial typical carcinoid tumors. J Thorac Cardiovasc Surg. 2006;132(1):113–115.
    1. Brokx HA, Risse EK, Paul MA, et al. Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. J Thorac Cardiovasc Surg. 2007;133(4):973–978.
    1. Dalar L, Ozdemir C, Abul Y, et al. Endobronchial treatment of carcinoid tumors of the lung. Thorac Cardiovasc Surg. 2016;64(2):166–171.
    1. Reuling EMBP, Dickhoff C, Plaisier PW, et al. Endobronchial treatment for bronchial carcinoid: patient selection and predictors of outcome. Respiration. 2018;95(4):220–227.
    1. Brokx HA, Paul MA, Postmus PE, Sutedja TG. Long-term follow-up after first-line bronchoscopic therapy in patients with bronchial carcinoids. Thorax. 2015;70(5):468–472.
    1. Jeon SM, Cheon JH. Rectal carcinoid tumors: pitfalls of conventional polypectomy. Clin Endosc. 2012;45(1):2–3.
    1. Basuroy R, Haji A, Ramage JK, Quaglia A, Srirajaskanthan R. Review article: the investigation and management of rectal neuroendocrine tumours. Aliment Pharmacol Ther. 2016;44(4):332–345.
    1. Jeon JH, Cheung DY, Lee SJ, et al. Endoscopic resection yields reliable outcomes for small rectal neuroendocrine tumors. Dig Endosc. 2014;26(4):556–563.
    1. Nakamura K, Osada M, Goto A, et al. Short- and long-term outcomes of endoscopic resection of rectal neuroendocrine tumours: analyses according to the WHO 2010 classification. Scand J Gastroenterol. 2016;51(4):448–455.
    1. Chen WJ, Wu N, Zhou JL, Lin GL, Qiu HZ. Full-thickness excision using transanal endoscopic microsurgery for treatment of rectal neuroendocrine tumors. World J Gastroenterol. 2015;21(30):9142–9149.
    1. Pan J, Zhang X, Shi Y, Pei Q. Endoscopic mucosal resection with suction vs. endoscopic submucosal dissection for small rectal neuroendocrine tumors: a meta-analysis. Scand J Gastroenterol. 2018;53(9):1139–1145.
    1. Zhang HP, Wu W, Yang S, Lin J. Endoscopic treatments for rectal neuroendocrine tumors smaller than 16 mm: a meta-analysis. Scand J Gastroenterol. 2016;51(11):1345–1353.
    1. Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg. 2010;89(3):998–1005.
    1. García-Yuste M, Matilla JM, Cueto A, et al. ; Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung for the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR) . Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg. 2007;31(2):192–197.
    1. Lee PC, Osakwe NC, Narula N, et al. Predictors of disease-free survival and recurrence in patients with resected bronchial carcinoid tumors. Thorac Cardiovasc Surg. 2016;64(2):159–165.
    1. Cusumano G, Fournel L, Strano S, Damotte D, Charpentier MC, Galia A, Terminella A, Nicolosi M, Regnard JF, Alifano M. Surgical resection for pulmonary carcinoid: long-term results of multicentric study-the importance of pathological N status, more than we thought. Lung. 2017;195(6):789–798.
    1. Campana D, Ravizza D, Ferolla P, et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine. 2016;51(1):131–139.
    1. Grozinsky-Glasberg S, Thomas D, Strosberg JR, et al. Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol. 2013;19(46):8687–8695.
    1. Bordi C, Falchetti A, Azzoni C, et al. Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol. 1997;21(9):1075–1082.
    1. Kim BS, Oh ST, Yook JH, Kim KC, Kim mg, Jeong JW, Kim BS. Typical carcinoids and neuroendocrine carcinomas of the stomach: differing clinical courses and prognoses. Am J Surg. 2010;200(3):328–333.
    1. Kim GH, Kim JI, Jeon SW, et al. ; Korean College of Helicobacter and Upper Gastrointestinal Research . Endoscopic resection for duodenal carcinoid tumors: a multicenter, retrospective study. J Gastroenterol Hepatol. 2014;29(2):318–324.
    1. Mahmud N, Tomizawa Y, Stashek K, Katona BW, Ginsberg GG, Metz DC. Endoscopic resection of duodenal carcinoid tumors: a single-center comparison between simple polypectomy and endoscopic mucosal resection. Pancreas. 2019;48(1):60–65.
    1. Bartel MJ, Puri R, Brahmbhatt B, et al. Endoscopic and surgical management of nonampullary duodenal neoplasms. Surg Endosc. 2018;32(6):2859–2869.
    1. Falconi M, Eriksson B, Kaltsas G, et al. ; Vienna Consensus Conference participants . ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–171.
    1. Gaujoux S, Partelli S, Maire F, et al. Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2013;98(12):4784–4789.
    1. Partelli S, Cirocchi R, Crippa S, et al. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. Br J Surg. 2017;104(1):34–41.
    1. Gaujoux S, Gonen M, Tang L, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol. 2012;19(13):4270–4277.
    1. Birnbaum DJ, Turrini O, Vigano L, et al. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Ann Surg Oncol. 2015;22(3):1000–1007.
    1. Lewis A, Raoof M, Ituarte PHG, et al. Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment. Ann Surg. 2018;270(6):1131–1137.
    1. Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Delle Fave G, Falconi M. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg. 2012;99(11):1480–1486.
    1. Hellman P, Lundström T, Ohrvall U, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002;26(8):991–997.
    1. Givi B, Pommier SJ, Thompson AK, Diggs BS, Pommier RF. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140(6):891–897; discussion 897.
    1. Daskalakis K, Karakatsanis A, Hessman O, et al. Association of a prophylactic surgical approach to stage IV small intestinal neuroendocrine tumors with survival. JAMA Oncol. 2018;4(2):183–189.
    1. Blažević A, Zandee WT, Franssen GJH, et al. Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. Endocr Relat Cancer. 2018;25(3):245–254.
    1. Daskalakis K, Karakatsanis A, Stålberg P, Norlén O, Hellman P. Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br J Surg. 2017;104(1):69–75.
    1. Landry CS, Lin HY, Phan A, et al. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg. 2013;37(7):1695–1700.
    1. Habbe N, Fendrich V, Heverhagen A, Ramaswamy A, Bartsch DK. Outcome of surgery for ileojejunal neuroendocrine tumors. Surg Today. 2013;43(10):1168–1174.
    1. Landerholm K, Zar N, Andersson RE, Falkmer SE, Järhult J. Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg. 2011;98(11):1617–1624.
    1. Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117(15):3332–3341.
    1. Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol. 2012;21(3):e131–e141.
    1. Wängberg B, Westberg G, Tylén U, et al. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg. 1996;20(7):892–899; discussion 899.
    1. Norton JA, Warren RS, Kelly mg, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134(6):1057–1063; discussion 1063.
    1. Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12(6):427–433.
    1. Gibson WE, Gonzalez RS, Cates JMM, Liu E, Shi C. Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract. Hum Pathol. 2018;79:109–115.
    1. Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Ann Surg. 2010;251(2):307–310.
    1. Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NE. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol. 2009;72(3):517–528.
    1. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187(1):88–92; discussion 92.
    1. Nazario J, Gupta S. Transarterial liver-directed therapies of neuroendocrine hepatic metastases. Semin Oncol. 2010;37(2):118–126.
    1. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003;9(4):261–267.
    1. Swärd C, Johanson V, Nieveen van Dijkum E, et al. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg. 2009;96(5):517–521.
    1. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. 1986;147(1):149–154.
    1. Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006;13(1):72–78.
    1. Maire F, Lombard-Bohas C, O’Toole D, et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology. 2012;96(4):294–300.
    1. Pericleous M, Caplin ME, Tsochatzis E, Yu D, Morgan-Rowe L, Toumpanakis C. Hepatic artery embolization in advanced neuroendocrine tumors: efficacy and long-term outcomes. Asia Pac J Clin Oncol. 2016;12(1):61–69.
    1. Fiore F, Del Prete M, Franco R, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47(1):177–182.
    1. Jia Z, Paz-Fumagalli R, Frey G, Sella DM, McKinney JM, Wang W. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors. J Gastroenterol Hepatol. 2017;32(9):1617–1623.
    1. Rajekar H, Bogammana K, Stubbs RS. Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. Int J Hepatol. 2011;2011:404916.
    1. Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007;47(4):460–466.
    1. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–188.
    1. Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass JA. Gallstones during octreotide therapy. Metabolism. 1992;41(9 Suppl 2):22–33.
    1. Caplin ME, Pavel M, Ćwikła JB, et al. ; CLARINET Investigators . Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–233.
    1. Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19(9):930–936.
    1. Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075–5086.
    1. Kiesewetter B, Duan H, Lamm W, et al. Oral ondansetron offers effective antidiarrheal activity for carcinoid syndrome refractory to somatostatin analogs. Oncologist. 2019;24(2):255–258.
    1. Wymenga AN, de Vries EG, Leijsma MK, Kema IP, Kleibeuker JH. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur J Cancer. 1998;34(8):1293–1294.
    1. Platt AJ, Heddle RM, Rake MO, Smedley H. Ondansetron in carcinoid syndrome. Lancet. 1992;339(8806):1416.
    1. Kulke MH, Hörsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14–23.
    1. Kulke MH, O’Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21(5):705–714.
    1. Pavel M, Gross DJ, Benavent M, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018;25(3):309–322.
    1. Pavel M, Hörsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511–1519.
    1. Oberg K, Norheim I, Lind E, et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep. 1986;70(11):1297–1304.
    1. Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761–771.
    1. Maton PN, Camilleri M, Griffin G, Allison DJ, Hodgson HJ, Chadwick VS. Role of hepatic arterial embolisation in the carcinoid syndrome. Br Med J (Clin Res Ed). 1983;287(6397):932–935.
    1. Strosberg J, Wolin E, Chasen B, et al. ; NETTER-1 Study Group . Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36(25):2578–2584.
    1. Shah GM, Shah RG, Veillette H, Kirkland JB, Pasieka JL, Warner RR. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol. 2005;100(10):2307–2314.
    1. Fiebrich HB, Van Den Berg G, Kema IP, et al. Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue. Aliment Pharmacol Ther. 2010;32(11-12):1398–1404.
    1. Møller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348(11):1005–1015.
    1. Munir A, Choudhary P, Harrison B, Heller S, Newell-Price J. Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol (Oxf). 2008;68(6):912–918.
    1. Zhao YP, Zhan HX, Zhang TP, et al. Surgical management of patients with insulinomas: result of 292 cases in a single institution. J Surg Oncol. 2011;103(2):169–174.
    1. Drash A, Wolff F. Drug therapy in leucine-sensitive hypoglycemia. Metabolism. 1964;13:487–492.
    1. Niitsu Y, Minami I, Izumiyama H, et al. Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. Endocr J. 2019;66(2):149–155.
    1. Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997;73(864):640–641.
    1. Sturgess NC, Kozlowski RZ, Carrington CA, Hales CN, Ashford ML. Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line. Br J Pharmacol. 1988;95(1):83–94.
    1. Verschoor L, Uitterlinden P, Lamberts SW, Del Pozo E. On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma. Clin Endocrinol (Oxf). 1986;25(5):555–560.
    1. Vezzosi D, Bennet A, Rochaix P, et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol. 2005;152(5):757–767.
    1. Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh). 1989;121(1):34–40.
    1. Hendren NS, Panach K, Brown TJ, et al. Pasireotide for the treatment of refractory hypoglycaemia from malignant insulinoma. Clin Endocrinol (Oxf). 2018;88(2):341–343.
    1. Tirosh A, Stemmer SM, Solomonov E, et al. Pasireotide for malignant insulinoma. Hormones (Athens). 2016;15(2):271–276.
    1. Novotny J, Janku F, Mares P, Petruzelka L. Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma. Support Care Cancer. 2005;13(9):760–762.
    1. Sadoff L, Gordon J, Goldman S. Amelioration of hypoglycemia in a patient with malignant insulinoma during the development of the ectopic ACTH syndrome. Diabetes. 1975;24(6):600–603.
    1. de Bruin C, Feelders RA, Waaijers AM, et al. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol. 2009;42(1):47–56.
    1. Ferrer-García JC, Tolosa-Torréns M, Hernando-Meliá C, Arribas-Palomar L, Sánchez-Juan C. Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma. Endocr Pract. 2011;17(2):e17–e20.
    1. van Schaik E, van Vliet EI, Feelders RA, et al. Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. J Clin Endocrinol Metab. 2011;96(11):3381–3389.
    1. Lutz SZ, Ullrich A, Häring HU, Ullrich S, Gerst F. Sunitinib specifically augments glucose-induced insulin secretion. Cell Signal. 2017;36:91–97.
    1. Chen J, Wang C, Han J, et al. Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. Expert Rev Anticancer Ther. 2013;13(6):737–743.
    1. Maton PN, Vinayek R, Frucht H, et al. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology. 1989;97(4):827–836.
    1. Metz DC, Comer GM, Soffer E, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther. 2006;23(3):437–444.
    1. Morocutti A, Merrouche M, Bjaaland T, Humphries T, Mignon M. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment Pharmacol Ther. 2006;24(10):1439–1444.
    1. Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol. 2007;102(12):2648–2654.
    1. Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther. 1993;7(6):597–610.
    1. Frost M, Lines KE, Thakker RV. Current and emerging therapies for PNETs in patients with or without MEN1. Nat Rev Endocrinol. 2018;14(4):216–227.
    1. Vinik AI, Tsai S, Moattari AR, Cheung P. Somatostatin analogue (SMS 201-995) in patients with gastrinomas. Surgery. 1988;104(5):834–842.
    1. Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005;52(64):1259–1265.
    1. Vinik AI, Tsai ST, Moattari AR, Cheung P, Eckhauser FE, Cho K. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med. 1986;81(6B):23–40.
    1. de Mestier L, Walter T, Brixi H, Lombard-Bohas C, Cadiot G. Sunitinib achieved fast and sustained control of VIPoma symptoms. Eur J Endocrinol. 2015;172(1):K1–K3.
    1. Zandee WT, Brabander T, Blažević A, et al. Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2019;104(4):1336–1344.
    1. Nguyen HN, Backes B, Lammert F, et al. Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. Dig Dis Sci. 1999;44(6):1148–1155.
    1. Santangelo WC, Unger RH, Orci L, Dueno MI, Popma JJ, Krejs GJ. Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration. Pancreas. 1986;1(5):464–469.
    1. Altimari AF, Bhoopalam N, O’Dorsio T, Lange CL, Sandberg L, Prinz RA. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Surgery. 1986;100(6):989–996.
    1. Wei J, Song X, Liu X, Ji Z, Ranasinha N, Wu J, Miao Y. Glucagonoma and glucagonoma syndrome: one center’s experience of six cases. J Pancreat Cancer. 2018;4(1):11–16.
    1. Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ. Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. Clin Endocrinol (Oxf). 2011;74(5):593–598.
    1. Nesi G, Marcucci T, Rubio CA, Brandi ML, Tonelli F. Somatostatinoma: clinico-pathological features of three cases and literature reviewed. J Gastroenterol Hepatol. 2008;23(4):521–526.
    1. Angeletti S, Corleto VD, Schillaci O, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut. 1998;42(6):792–794.
    1. Rinke A, Müller HH, Schade-Brittinger C, et al. ; PROMID Study Group . Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–4663.
    1. Caplin ME, Pavel M, Ćwikła JB, et al. ; CLARINET Investigators . Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191–199.
    1. Kulke MH, Ruszniewski P, Van Cutsem E, et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2017;28(6):1309–1315.
    1. Cives M, Kunz PL, Morse B, et al. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015;22(1):1–9.
    1. Kaemmerer D, Specht E, Sänger J, et al. Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers. J Clin Endocrinol Metab. 2015;100(3):831–840.
    1. Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, et al. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. Lung Cancer. 2017;109:128–136.
    1. Ferolla P, Brizzi MP, Meyer T, et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2017;18(12):1652–1664.
    1. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416–2423.
    1. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617–4624.
    1. Baum RP, Kulkarni HR, Singh A, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018;9(24):16932–16950.
    1. Garske-Román U, Sandström M, Fröss Baron K, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970–988.
    1. Strosberg J, El-Haddad G, Wolin E, et al. ; NETTER-1 Trial Investigators . Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135.
    1. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol. 2004;22(13):2724–2729.
    1. Bergsma H, Konijnenberg MW, van der Zwan WA, et al. Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016;43(10):1802–1811.
    1. Bergsma H, Konijnenberg MW, Kam BL, et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging. 2016;43(3):453–463.
    1. Bergsma H, van Lom K, Raaijmakers MHGP, et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2018;59(3):452–458.
    1. Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5–19.
    1. Severi S, Sansovini M, Ianniello A, et al. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging. 2015;42(13):1955–1963.
    1. van der Zwan WA, Brabander T, Kam BLR, et al. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019;46(3):704–717.
    1. Hofving T, Arvidsson Y, Almobarak B, et al. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines. Endocr Relat Cancer. 2018;25(4):X1–X2.
    1. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology. 1998;32(2):133–138.
    1. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26(20):3403–3410.
    1. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513.
    1. Raymond E, Kulke MH, Qin S, et al. Efficacy and safety of sunitinib in patients with well-differentiated pancreatic neuroendocrine tumours. Neuroendocrinology. 2018;107(3):237–245.
    1. Vinik A, Bottomley A, Korytowsky B, et al. Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial. Target Oncol. 2016;11(6):815–824.
    1. Yao JC, Shah MH, Ito T, et al. ; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–523.
    1. Pavel ME, Hainsworth JD, Baudin E, et al. ; RADIANT-2 Study Group . Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–2012.
    1. Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol. 2016;34(32):3906–3913.
    1. Pavel M, Unger N, Borbath I, et al. Safety and QOL in patients with advanced NET in a phase 3b expanded access study of everolimus. Target Oncol. 2016;11(5):667–675.
    1. Angelousi A, Kamp K, Kaltsatou M, O’Toole D, Kaltsas G, de Herder W. Sequential everolimus and sunitinib treatment in pancreatic metastatic well-differentiated neuroendocrine tumours resistant to prior treatments. Neuroendocrinology. 2017;105(4):394–402.
    1. Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med. 1983;309(3):129–133.
    1. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion. 2000;62(Suppl 1):92–97.
    1. Faiss S, Pape UF, Böhmig M, et al. ; International Lanreotide and Interferon Alfa Study Group . Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors–the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21(14):2689–2696.
    1. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol. 1989;7(7):865–868.
    1. Pavel ME, Baum U, Hahn EG, Schuppan D, Lohmann T. Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res. 2006;26(1):8–13.
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
    1. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104.
    1. Cives M, Strosberg J, Al Diffalha S, Coppola D. Analysis of the immune landscape of small bowel neuroendocrine tumors. Endocr Relat Cancer. 2019;26(1):119–130.
    1. Bösch F, Brüwer K, Altendorf-Hofmann A, et al. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia. Endocr Relat Cancer. 2019;26(3):293–301.
    1. Chauhan A, Horn M, Magee G, et al. Immune checkpoint inhibitors in neuroendocrine tumors: a single institution experience with review of literature. Oncotarget. 2018;9(10):8801–8809.
    1. Mehnert JM, Rugo HS, O’Neil BH, et al. Pembrolizumab for patients with PD-L1-positive advanced carcinoids or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study. J Clin Oncol. 2017;28(Suppl 5):abstr 4270.
    1. Wong MH, Chan DL, Lee A, et al. Systematic review and meta-analysis on the role of chemotherapy in advanced and metastatic neuroendocrine tumor (NET). Plos One. 2016;11(6):e0158140.
    1. Heetfeld M, Chougnet CN, Olsen IH, et al. ; other Knowledge Network members . Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657–664.
    1. Fjällskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001;92(5):1101–1107.
    1. Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68(2):227–232.
    1. Hijioka S, Hosoda W, Matsuo K, et al. Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study. Clin Cancer Res. 2017;23(16):4625–4632.
    1. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303(21):1189–1194.
    1. Moertel CG, Douglas HO Jr, Hanley J, Carbone PP. Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. Cancer. 1977;40(2):605–608.
    1. Clewemar Antonodimitrakis P, Sundin A, Wassberg C, Granberg D, Skogseid B, Eriksson B. Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity. Neuroendocrinology. 2016;103(3-4):345–353.
    1. Shibuya H, Hijioka S, Sakamoto Y, et al. Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy. Cancer Chemother Pharmacol. 2018;82(4):661–668.
    1. Dilz LM, Denecke T, Steffen IG, et al. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer. 2015;51(10):1253–1262.
    1. Faure M, Niccoli P, Autret A, Cavaglione G, Mineur L, Raoul JL. Systemic chemotherapy with FOLFOX in metastatic grade ½ neuroendocrine cancer. Mol Clin Oncol. 2017;6(1):44–48.
    1. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG; Eastern Cooperative Oncology Group . Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23(22):4897–4904.
    1. Krug S, Boch M, Daniel H, et al. Streptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms–predictive and prognostic markers for treatment stratification. Plos One. 2015;10(12):e0143822.
    1. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117(2):268–275.
    1. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15(1):338–345.
    1. Crespo G, Jiménez-Fonseca P, Custodio A, et al. Capecitabine and temozolomide in grade ½ neuroendocrine tumors: a Spanish multicenter experience. Future Oncol. 2017;13(7):615–624.
    1. Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang YZ, Woltering EA. The role of capecitabine/temozolomide in metastatic neuroendocrine tumors. Oncologist. 2016;21(6):671–675.
    1. Abbasi S, Kashashna A, Albaba H. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience. Pancreas. 2014;43(8):1303–1305.
    1. Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol. 2013;71(3):663–670.
    1. Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211). J Clin Oncol. 2018;36(15 suppl):4004.
    1. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009;89(4):471–476.
    1. van Adrichem RC, Kamp K, Vandamme T, Peeters M, Feelders RA, de Herder WW. Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. Ann Oncol. 2016;27(4):746–747.
    1. Alvarez MJ, Subramaniam PS, Tang LH, et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat Genet. 2018;50(7):979–989.
    1. Haber AL, Biton M, Rogel N, et al. A single-cell survey of the small intestinal epithelium. Nature. 2017;551(7680):333–339.
    1. Grün D, Lyubimova A, Kester L, et al. Single-cell messenger RNA sequencing reveals rare intestinal cell types. Nature. 2015;525(7568):251–255.
    1. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23(12):2754–2762.
    1. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–762.
    1. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110(5):2858–2902.
    1. Nicolas GP, Schreiter N, Kaul F, et al. Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59(6):915–921.
    1. Dalm SU, Bakker IL, de Blois E, et al. 68Ga/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology. J Nucl Med. 2017;58(2):293–299.
    1. Faggiano A, Di Maio S, Mocerino C, et al. ; Elios . Therapeutic sequences in patients with grade 1–2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine. 2019; doi: 10.1007/s12020-12019-01894-12020.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner